Karin Conde-Knape

About

Pharmaceutical Industry Executive with a demonstrated track record in Cardiovascular and Metabolism. Strong professional skilled in Biomarkers, Translational Biology, Validation, Pharmacology, Target Identification and External Innovation.

Experience

• Novo Nordisk (7 yrs 10 mos)
  • Senior Vice President Early Development
    Mar 2025 - Oct 2025 · 8 mos

  • Senior Vice President Global Drug Discovery
    Mar 2021 - Mar 2025 · 4 yrs 1 mo

  • Corporate Vice President Diabetes, Cardio-renal and Translational Research
    Jan 2020 - Mar 2021 · 1 yr 3 mos

    Responsible for research Therapeutic area strategy and execution within the areas of Diabetes, Cardiovascular and kidney disease as well as translational science.

• Vice President Cardiovascular and Metabolism at Johnson and Johnson Medical
  Sep 2013 - Dec 2017 · 4 yrs 4 mos

  Responsible for identifying, establishing and managing External Scientific opportunities from Early research to Clinical POC in the aread of Cardiovascular and Metabolism.

• Roche (Basel Area, Switzerland)
  • Acting Head of Discovery
    Sep 2012 - Aug 2013 · 1 yr

    Responsible for all Discovery efforts in the Cardiovascular and Metabolism DTA

  • Research Director, Head of In vivo Pharmacology
    Apr 2010 - Aug 2013 · 3 yrs 5 mos

    Responsible for setting the in vivo pharmacology strategy of projects in the areas of Diabetes, CV, Renal, Atherosclerosis and Dyslipidemia. Supporting through in vivo pharmacology projects from target validation all the way to phase 3. Managing multiple collaborations with Academic institutions and CROs.